Published in Oncology Business Week, March 12th, 2006
With this notice, the company is now in a position to initiate the clinical trial. The company plans to test the drug in up to 30 patients with late-stage cancers to evaluate safety as well as early efficacy. The trial is designed to study a mixed group of tumors that will include the most common cancers such as ovarian, lung, and breast.
Chemokine expects to expand its CTCE-9908 clinical program with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week